Aggregated price index
Aggregated price index with volume information
- Gene Therapy stocks down 1.8% on average while median return down 1.7% in a day
- Gene Therapy stocks down 0.4% on average while median return down 0.4% in a week
- Gene Therapy stocks up 13.7% on average while median return up 16.9% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $NTLA 57.2%, $ORTX 55.6%, $SLDB 35.3%, $CRSP 33.2%, $BNTC 30.5%
- 1M losers are : Losers for past month are $RCKT -1.8%, $RARE -10.0%, $ADVM -18.8%, $QURE -19.2%, $SRPT -46.7%
- 1W winners are : Winners for past week are $CAPR 14.7%, $SRPT 9.8%, $ABEO 8.5%, $NTLA 4.5%, $BLUE 4.1%
- 1W losers are : Losers for past week are $SGMO -7.2%, $BMRN -7.7%, $RARE -8.4%, $QURE -8.4%, $EDIT -15.9%
Index correlation analysis
Correlation for the past month is 30.1%, for the past 3 months is 20.2%
In the past month for a 5 days rolling window, the highest corrrelation is 56.7%, the lowest correlation is -2.1%, the latest correlation is 0.5%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 87.4% between CRSP and NTLA
The lowest correlation is -35.9% between ADVM and BMRN
LOS ANGELES, CA / ACCESSWIRE / January 15, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT) for violations of the securities laws.
The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Shares up.
Stocks of start-ups wielding tools like Crispr-Cas9 that allow companies to edit DNA and attack genetic diseases and cancer are suddenly hot. But the science is moving with incredible speed and the competition is rising.
CRSP is now trading around $215 so I think another look at the stock is warranted and perhaps a change in strategy. In this updated daily Japanese candlestick chart of CRSP, below, we can see some weakening of the indicators. Trading volume has expanded this month as prices have increased.
In this article, we present to you the 15 Best Undervalued Stocks to Buy Now. If you’re in a hurry, click to skip ahead and jump to the 5 Best Undervalued Stocks to Buy Now. Investing in the stock market could be difficult. We can classify investors based on their portfolios. The low risk-takers who […]
After talking to customers, analysts at the bank believe that the majority of software company’s customers will stick with it.
Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 13) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Atea Pharmaceuticals Inc (NASDAQ: AVIR) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * Bioatla Inc (NASDAQ: BCAB) * Biodesix Inc (NASDAQ: BDSX) (announced a collaboration with HiberCell for the development of an enzyme-linked immunosorbent assay as a companion diagnostic in future registrational tri...
Interactions with FDA anticipated by mid-2021 to determine the BLA filing strategy for OTL-200BOSTON and LONDON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OTL-200, an investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of early-onset metachromatic leukodystro...